Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt Preparing Environment to Deliver Japanese-Originated Drugs: Amari
March 6, 2015
- Aso Shrugs Off Question on Ibuki’s Annual NHI Price Revision Remarks
March 6, 2015
- Ishin Submits Bill to Optimize Clinical Research
March 5, 2015
- NCGM Opts Out of Special Mixed Care Scheme in Tokyo Economic Zone
March 5, 2015
- Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme
March 3, 2015
- Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
- MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime
March 2, 2015
- PMDA Evaluating Sitagliptin for Risk of Thrombocytopenia
March 2, 2015
- Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
- PAFSC Second Committee Backs Approval of Celgene’s Pomalidomide
February 27, 2015
- Roundtable Discussion for Healthcare Policy for 2035 Kicked Off
February 27, 2015
- MHLW OKs 60 New APIs in 2014, Doubling from Year Ago
February 26, 2015
- MHLW Prods Self-Inspections at Insurance Pharmacies after Medication History Fuss
February 25, 2015
- Drug Price Settlement Rate at 76.2% in December: MHLW
February 24, 2015
- Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
- New Division for Cancer and Specific Diseases Control to Handle Hepatitis Measures after Reorganization of HSB
February 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 9 - 22
February 23, 2015
- Shiozaki Says Annual NHI Price Cuts Could Hit Distributors, Mar Innovation Drive; Ministry to Consider Plan based on Govt’s Economic Blueprint
February 23, 2015
- PAFSC Committee’s Nod for New Xarelto Indication Put on Hold
February 23, 2015
- Drug Dispensing Expenditure Up 1.8% in April-September 2014; Down 4.1 Points from Previous Year
February 23, 2015
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…